BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma

JAMA Oncology 2026 Open access

Read full text
Authors: Justin Ferdinandus, Horst Müller, Janina Jablonski, Andrea Kerkhoff, Sebastian Scholl, Yon-Dschun Ko, Max S. Topp, Vladan Vucinic, Wolfram E Jung, Roland Schroers, Andreas Rank, Michael Fuchs
+4 more Gundolf Schneider, V. Diehl, Peter Borchmann, Karolin Behringer
DOI: 10.1001/jamaoncol.2025.6327
Cited by: 1
References: 6

Abstract

This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research CNS Lymphoma Diagnosis and Treatment

Publication details

Journal / source
JAMA Oncology
Publisher
American Medical Association (AMA)
Volume
12
Issue
4
Pages
415–415
Publication date
5 February 2026
Language
EN